IL6 and systemic sclerosis: As far as IL-6 is concerned, treatment of dermal SSc fibroblasts with tocilizumab, a humanized antibody directed against IL-6 receptor, downregulated the expression of different pro-fibrotic genes and reduced fibroblast migration and contractility [199].